C4 Therapeutics, Inc.
CCCC
$2.61
-$0.08-2.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.95M | 30.11M | 34.24M | 39.78M | 35.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.95M | 30.11M | 34.24M | 39.78M | 35.58M |
| Cost of Revenue | 8.98M | 13.67M | 19.52M | 17.08M | 12.54M |
| Gross Profit | 26.97M | 16.44M | 14.72M | 22.71M | 23.05M |
| SG&A Expenses | 36.20M | 37.39M | 40.24M | 41.17M | 42.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.44M | 149.16M | 157.86M | 156.34M | 152.76M |
| Operating Income | -104.49M | -119.05M | -123.62M | -116.56M | -117.18M |
| Income Before Tax | -104.87M | -118.95M | -111.45M | -103.15M | -105.19M |
| Income Tax Expenses | 121.00K | 131.00K | 131.00K | 131.00K | 131.00K |
| Earnings from Continuing Operations | -104.99 | -119.08 | -111.58 | -103.28 | -105.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.99M | -119.08M | -111.58M | -103.28M | -105.32M |
| EBIT | -104.49M | -119.05M | -123.62M | -116.56M | -117.18M |
| EBITDA | -102.53M | -117.04M | -121.63M | -114.73M | -115.36M |
| EPS Basic | -1.36 | -1.67 | -1.58 | -1.47 | -1.52 |
| Normalized Basic EPS | -0.77 | -0.97 | -1.01 | -0.96 | -0.96 |
| EPS Diluted | -1.36 | -1.67 | -1.58 | -1.47 | -1.52 |
| Normalized Diluted EPS | -0.77 | -0.97 | -1.01 | -0.96 | -0.96 |
| Average Basic Shares Outstanding | 331.19M | 285.01M | 282.07M | 279.88M | 277.48M |
| Average Diluted Shares Outstanding | 331.19M | 285.01M | 282.07M | 279.88M | 277.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |